For what disease has the bispecific monoclonal antibody Blincyto approved for treatment?

Question

Quizplus · Accepted Answer

Blincyto (blinatumomab) is approved for the treatment of acute lymphocytic leukemia (ALL), a type of cancer that affects the white blood cells. It is a bispecific monoclonal antibody that works by binding to both CD19 (a protein found on the surface of leukemia cells) and CD3 (a protein found on T cells), which helps the body's own immune system to attack and destroy the cancer cells.

For What Disease Has the Bispecific Monoclonal Antibody Blincyto Approved